Suchergebnisse - "Emadi, Ashkan"

PubPharm (7)

1

Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy : a phase 2 study

enthalten in: Blood advances | 2023

von Altman, J. | Zuckerman, T. | Koprivnikar, J. | +23

2

Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)

enthalten in: Leukemia & lymphoma | 2021

von Jacoby, M. | Finn, L. | Emadi, A. | +6

3

A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia

enthalten in: Cancer | 2020

von Narayan, R. | Blonquist, T. | Emadi, A. | +32

4

Recent drug approvals for newly diagnosed acute myeloid leukemia : gifts or a Trojan horse?

enthalten in: Leukemia | 2020

von Estey, E. | Karp, J. | Emadi, A. | +2

5

Treatment of CD19-positive mixed phenotype acute leukemia with blinatumomab

enthalten in: American journal of hematology | 2019

von El Chaer, F. | Ali, O. | Sausville, E. | +10

6

Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response

enthalten in: Blood | 2012

von Fathi, A. | Sadrzadeh, H. | Borger, D. | +18

7

The clinically relevant pharmacogenomic changes in acute myelogenous leukemia

enthalten in: Pharmacogenomics | 2012

von Emadi, A. | Karp, J.

1
[1]